デフォルト表紙
市場調査レポート
商品コード
1020412

尿失禁治療機器の世界市場:成長、動向、COVID-19の影響、予測(2021年~2026年)

Urinary Incontinence Treatment Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
尿失禁治療機器の世界市場:成長、動向、COVID-19の影響、予測(2021年~2026年)
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

尿失禁治療機器の市場規模は、2020年に31億7,541万米ドルとなり、2021年~2026年の予測期間中に6.57%のCAGRで成長し、2026年までに4兆6,638億8,000万米ドルになると予想されています。

2020年のCOVID-19パンデミックの初期、いくつかの国が封鎖されていました。彼らは他国との貿易を停止し、旅行制限を実施したため、2020年前半に診断と外科的処置が減少しました。

British Journal of Surgeryに掲載された調査によると、2020年5月、COVID-19による病院サービスの中断のピークの12週間に基づいて、世界中で約2,840万件の待期的手術がキャンセルまたは延期されました。2020年5月に国際コンソーシアムが実施した調査によると、COVID-19のパンデミックの結果、インドで計画されている58万件以上の手術がキャンセルまたは延期されました。

2020年7月にInternational Journal of Surgeryに掲載されたAhmed Al-Jabir et al.の研究論文によると、2020年のCOVID-19パンデミック期間中、遅延または延期された泌尿器科手術には、尿失禁、腹圧性膀胱、過活動膀胱(OAB)、神経因性膀胱などがあります。 慢性的なカテーテル交換の場合、それぞれ2週間~4週間遅れました。

市場の成長に寄与する主な要因は、尿失禁の有病率の上昇です。男性の尿路感染症、骨盤底筋と尿道括約筋の衰弱、閉経、妊娠と出産、および根治的前立腺切除術後の手術などの多くの要因が、尿失禁症状の発症につながります。ゴーセンバーグ失禁調査センターによると、2018年には4億2,300万人以上が尿失禁に苦しんでおり、そのうち3億300万人が女性でした。

国立バイオテクノロジー情報センター(NCBI)によると、「閉経後の女性の尿失禁(2019)」というタイトルの記事で、パーキンソン病、糖尿病、多発性硬化症などのさまざまな病気の発生率が上昇しており、男性と女性の尿失禁の有病率が増加する可能性があることがわかりました。これにより、予測期間中に尿失禁治療機器の需要が増加すると予想されます。さらに、低侵襲手術の需要の高まりと技術の進歩の増加は、市場の成長を後押しします。

さらに、市場のプレーヤーは、調査対象の市場で製品ポートフォリオを拡大するために、製品の発売、開発、買収、合併、コラボレーションなどのさまざまな戦略を採用しており、市場の成長を後押ししています。例えば、2018年2月、Cogentix Medical Inc.は、切迫性尿失禁の治療のための緊急PC神経調節システム(電気刺激機器)の商品化を発表しました。

ただし、機器や病気に関連する社会的不名誉についての認識の欠如、および手順に関連するリスクと合併症などの要因は、予測期間中の市場の成長を妨げると予想されます。

当レポートでは尿失禁治療機器の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、製品・エンドユーザー・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 尿失禁の有病率の増加と老人人口の増加
    • 低侵襲手術と製品開発に対する需要の高まり
  • 市場の抑制要因
    • 病気に関連する機器と社会的スティグマについての認識の欠如
    • 手順別リスクと合併症
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 製品別
    • 尿道スリング
    • 電気刺激機器
    • 人工尿道括約筋
    • カテーテルおよびその他
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Boston Scientific Corporation
    • Becton, Dickinson and Company
    • Colopast AS.
    • Promedon Group
    • AMI GmbH
    • Johnson &Johnson
    • Zephyr Surgical Implants
    • Medtronic PLC
    • Caldera Medical Inc
    • Hollister Incorporated
    • Nipro Corporation
    • Karl Storz SE &Co. KG
    • B Braun Melsungen AG
    • Baxter International Inc
    • ConvaTec Group Plc

第7章 市場機会と動向

目次
Product Code: 68593

The Urinary Incontinence Treatment Devices Market was valued at USD 3,175.41 million in 2020 and is expected to reach 4,663.88 billion by 2026, registering a CAGR of 6.57% during the forecast period.

In the initial days of the COVID-19 pandemic 2020, several countries were in lockdown. They suspended trade with other countries and implemented travel restrictions, leading to the decline in diagnosis and surgical procedures in the first half of 2020.

According to the study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, more than 580,000 planned surgeries in India were canceled or delayed as a result of the COVID-19 pandemic, according to a study conducted by an international consortium in May 2020.

According to a research article by Ahmed Al-Jabir et al., published in International Journal of Surgery July 2020, globally, during COVID-19 pandemic 2020, some of the urological procedures which were delayed or postponed include urinary incontinence, stress incontinence, overactive bladder (OAB) and neurogenic bladder. In case of chronic catheter change it was delayed for 2-4 weeks, respectively.

The major factor attributing to the growth of the market is the rising prevalence of urinary incontinence. Numerous factors such as urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy and childbirth and post radical prostatectomy surgery in men lead to the development of urinary incontinence symptoms. According to the Gothenburg Continence Research Center, in 2018 more than 423 million people suffered from urinary incontinence of which, 303 million were women.

According to the National Center for Biotechnology Information (NCBI), in the article titled 'Urinary Incontinence in Postmenopausal Women (2019)', it was found that there is a rise in the incidence of various diseases, such as Parkinson's disease, diabetes, multiple sclerosis etc., which may lead to increased prevalence of urinary incontinence in males and females. This is expected to increase demand for urinary incontinence treatment devices over the forecast period. Furthermore, rising demand for minimally invasive procedures and increasing technological advancements boost the market growth.

Moreover, the market players are adopting various strategies, such as product launches, developments, acquisitions, merges, and collaborations, to expand their product portfolio in the market studied, and is boosting the market growth. For instance, in February 2018, Cogentix Medical Inc. announced the commercialization of an urgent PC neuromodulation system (electric stimulation device) for the treatment of urge incontinence.

However, factors such as lack of awareness about devices and social stigma associated with the disease, and the risks and complications related to the procedures, are expected to impede market growth over the forecast period.

Key Market Trends

Urethral Slings Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period

Urethral slings are highly recommended for surgical treatment for treating stress urinary incontinence. The urethral sling is considered the gold standard method that has replaced all conventional procedures, such as colposuspension and vaginal mesh.

According to a 2020 research study by Jeremy Yuen-Chun Teoh et al., titled 'A Global Survey on the Impact of COVID-19 on Urological Services', outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, and sexual medicine, benign scrotal conditions, renal stone, and bladder stone were most affected. Moreover, there was significant cut-down across various types of outpatient investigations and procedures during COVID-19 pandemic 2020, particularly surgical procedures for female urinary incontinence, infertility, renal stones, and bladder stones had the highest rates of cut-down services.

Urethral slings surgery is also known as mid-urethral sling surgery. Mid-urethral sling surgery usually takes around 30 minutes to perform and is considered an outpatient procedure. In this surgery, a sling is placed around the urethra to lift it back into a normal position and exert pressure on the urethra to aid urine retention. The sling is attached to the abdominal wall.

The sling material may be muscle, ligament, or tendon tissue taken from the woman or from an animal, such as a pig. It may also be composed of synthetic material, such as plastic that is compatible with body tissues or of absorbable polymer that disintegrates over time.

According to the Gothenburg Continence Research Center, in 2018, more than 423 million people suffered from urinary incontinence, of which 303 million were women. The rising prevalence of urinary incontinence among the women population is increasing the demand for urethral sling surgery.

Furthermore, benefits such as quick recovery time are increasing its demand among patient population. Apart from the low-risk rates and advantages of the sling procedures, the increasing demand for minimally invasive surgeries is also boosting the segment growth.

In February 2019, the company Boston Scientific had launched a redesign of its mesh sling system, which is a surgical implant for stress urinary incontinence in male patients. In addition, the surgical mesh is implanted to support the urethra or bladder neck in order to correct stress urinary incontinence (SUI).

Moreover, the growing volume of urinary incontinence and cumulative research in the arena of urinary incontinence treatment adoptions are the major factors for the growth of the urethral slings segment.

North America is Expected to Hold a Significant Share in the Market Over the Forcasted Period

The major driving factors attributing to the market growth in North America region are increasing the prevalence of urinary incontinence, increasing geriatric population, and the increasing demand for minimally invasive surgeries in the region.

Some of the market players recorded a revenue decline in the urology platform due to the COVID-19 outbreak. For instance, Coloplast Corp., interventional urology segment generated a negative organic growth of -7% in the financial year 2019-20. The negative growth was mainly due to a decrease in sales of Altis single-incision slings and other products, due to the cancellation of elective surgeries and procedures in the United States due to the COVID-19 outbreak. Moreover, due to the COVID-19 outbreak, the elective procedures outside of the United States were also postponed in several countries.

Furthermore, due to the improved outlook for the interventional urology segment, the company's commercial investments were temporarily put on hold due to the COVID-19 pandemic. These investments were initiated again during Q4-2020.

As per the Government of Canada's statistics report, as of July 2019, Canadian geriatric population included 6,592,611 people, which accounted for 17.5% of the Canadian population. The proportion of seniors in Canada has been increasing over time. Aging increases the risk of bladder problems such as bladder control issues, such as leakage or urinary incontinence thereby positively influencing the Canadian market for urinary incontinence treatment devices market.

As per the article published in Medscape in June 2021 on "What is the prevalence of urinary incontinence?", the Urinary incontinence has been estimated to affect 10-13 million people in the United States. Also, the cost of treating urinary incontinence in United States alone is USD 16.3 billion, 75% of which is spent on treatment of women.

Companies adopting strategies, such as research and development, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position. In February 2020, Atlantic Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted over-the-counter (OTC) clearance to INNOVO, a non-invasive, clinically proven and wearable device for the treatment of stress urinary incontinence (SUI) in adult females.

Competitive Landscape

The Urinary Incontinence Treatment Devices market is moderately competitive. Some of the companies which are currently dominating the market are Boston Scientific Corporation, Becton, Dickinson and Company., Coloplast Corp, Promedon Group, A.M.I. GmbH, Johnson & Johnson, ZSI Surgical Implants S.R.L.,Medtronic plc, Hollister Incorporated.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Urinary Incontinence and Rise in Geriatric Population
    • 4.2.2 Rise in Demand for Minimally Invasive Surgery and Product Development
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness about Devices and Social Stigma Associated with the Disease
    • 4.3.2 Risks and Complications from the Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Urethral Slings
    • 5.1.2 Electrical Stimulation Devices
    • 5.1.3 Artificial Urinary Sphincters
    • 5.1.4 Catheters and Others
  • 5.2 By End-User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centres
    • 5.2.3 Other End-Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Colopast AS.
    • 6.1.4 Promedon Group
    • 6.1.5 A.M.I. GmbH
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Zephyr Surgical Implants
    • 6.1.8 Medtronic PLC
    • 6.1.9 Caldera Medical Inc
    • 6.1.10 Hollister Incorporated
    • 6.1.11 Nipro Corporation
    • 6.1.12 Karl Storz SE & Co. KG
    • 6.1.13 B Braun Melsungen AG
    • 6.1.14 Baxter International Inc
    • 6.1.15 ConvaTec Group Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS